Company Profile
Corcept Stock Price, News & Analysis
- Ticker:
- CORT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
107.95 USD (-2.48%)
Close
Last updated: August 6, 2026
7.64B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CORT closed down 2.48% at $107.95. No new same-company headline was identified in the current news window.
Company overview
Cortisol Modulation Platform
Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology.
Cushing’s Syndrome Franchise
Corcept has an established commercial business treating hypercortisolism in patients with Cushing’s syndrome. Relacorilant has also completed the pivotal GRACE program, supporting the company’s effort to expand and modernize this endocrine franchise.
LIFYORLI in Ovarian Cancer
LIFYORLI, or relacorilant, is FDA approved with nab-paclitaxel for platinum-resistant ovarian cancer. The approval establishes Corcept’s first oncology product and validates cortisol modulation as a way to improve response to anticancer therapy.
Oncology Expansion
The BELLA program is evaluating relacorilant combinations in platinum-resistant and platinum-sensitive ovarian cancer and in previously treated endometrial cancer. These studies are intended to broaden use across gynecologic malignancies and treatment settings.
Metabolic and Neurologic Pipeline
Miricorilant is in the Phase 2b MONARCH trial for metabolic dysfunction-associated steatohepatitis. Dazucorilant is being prepared for Phase 3 testing in amyotrophic lateral sclerosis following a survival signal in the Phase 2 DAZALS study.
Future catalysts
European decision on relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer expected by year-end 2026.
BELLA Part A results expected by year-end 2026.
Phase 2b MONARCH results for miricorilant in MASH expected by year-end 2026.
Initiation of a Phase 3 dazucorilant trial in ALS planned later in 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Corcept (CORT)?
Corcept (CORT) most recently closed at 107.95 USD, a -2.48% move versus the previous session.
What is the market cap of Corcept (CORT)?
Corcept currently has a market capitalization of 7.64B USD on BioPharmSignal.
What does Corcept do?
Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients with Cushing’s...
On which exchange is CORT stock listed?
Corcept (CORT) is associated with NASDAQ, United States, Biopharma.
What is Cortisol?
Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol.
Which conditions is Corcept targeting with Cortisol?
Corcept is associated with oncology, cancer therapeutics, metabolic disease based on its company overview and current catalyst commentary.
How does Corcept describe recent progress with Cortisol?
European decision on relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer expected by year-end 2026. BELLA Part A results expected by year-end 2026. Phase 2b MONARCH results for miricorilant in MASH expected by year-end 2026. Initiation of a Phase 3 dazucorilant trial in ALS planned later in 2026.
What is Modulation?
Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol.